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Background—One lung ventilation (OLV) results in inflammatory and mechanical injury, 
leading to intraoperative and postoperative complications in children. No interventions have been 
studied in children to minimize such injury.
Objective—We hypothesized that a single 2-mg/kg dose of methylprednisolone given 45–60 
minutes prior to lung collapse will minimize injury from OLV and improve physiological stability.
Methods—Twenty-eight children scheduled to undergo OLV were randomly assigned to receive 
2 mg/kg methylprednisolone (MP) or normal saline (placebo group) prior to OLV. Anesthetic 
management was standardized, and data were collected for physiological stability (bronchospasm, 
respiratory resistance, and compliance). Plasma was assayed for inflammatory markers related to 
lung injury at timed intervals related to administration of methylprednisolone.
Results—Three children in the placebo group experienced clinically significant intraoperative 
and postoperative respiratory complications. Respiratory resistance was lower (P = 0.04) in the 
methylprednisolone group. Pro-inflammatory cytokine IL-6 was lower (P = 0.01) and anti-
inflammatory cytokine IL-10 was higher (P = 0.001) in the methylprednisolone group. Tryptase, 
measured before and after OLV, was lower (P = 0.03) in the methylprednisolone group while 
increased levels of tryptase were seen in placebo group after OLV (did not achieve significance). 
There were no side effects observed that could be attributed to methylprednisolone in this study.
Conclusions—Methylprednisolone at 2 mg/kg given as a single dose prior to OLV provides 
physiological stability to children undergoing OLV. In addition, methylprednisolone results in 
lower pro-inflammatory markers and higher anti-inflammatory markers in the children's plasma.
Keywords
Pediatrics; one lung ventilation; methylprednisolone; cytokines; tryptases; oxidative stress
Introduction
Video-assisted thoracoscopic surgery has made one lung ventilation (OLV) necessary in 
children.1 Injury from OLV includes endothelial dysfunction, alveolar edema, disruption of 
type-1 pneumocytes, and infiltration of polymorphonuclear cells.2-4 In this study, we took 
advantage of the fact that OLV is a pre-planned iatrogenic injury, allowing an opportunity to 
institute an intervention to minimize known associated injuries.
The intervention proposed here, a single dose (2 mg/kg) of methylprednisolone (MP) given 
prior to OLV, was studied in our piglet model of OLV.5 It demonstrated reduced 
inflammatory markers both in plasma and the lung tissue and was shown to further decrease 
neutrophil infiltrates in the alveoli.5 Our primary hypothesis for this clinical study was that 
MP given in a single dose of 2 mg/kg prior to OLV would result in improved physiological 
stability by decreasing the incidence of bronchospasm and failure of OLV in children. Our 
second hypothesis was that MP would decrease the pro-inflammatory markers tumor 
necrosis factor (TNF)-α and interleukin (IL)-6 while increasing the anti-inflammatory 
marker IL-10 during and after OLV in children.6,7 We also examined the influence of MP 
on serum tryptase, which is a known marker of lung injury, resulting from ischemia-
Theroux et al. Page 2
Paediatr Anaesth. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
reperfusion8 as was evident from our own prior clinical experience with OLV-related 
complications.*
Methods
Study Design
The study was a randomized, double-blinded, placebo-controlled clinical trial of parallel 
design. After we obtained IRB approval, a study coordinator obtained parental consent and 
child's consent/assent to enroll children aged 3–18 years. The coordinator collected data and 
performed all assays of inflammatory markers and was blinded to the grouping of the 
subjects. Only the anesthesiologist responsible for the child was made aware of the 
grouping. Once enrolled, the children were randomized using a random number table and a 
simple random allocation to either the placebo group, who received 2 ml of normal saline 
intravenously, or to the MP group, who received a single dose of 2 mg/kg MP intravenously 
(maximum dose 80 mg) 45–60 minutes prior to OLV. The placebo and MP were prepared 
by a pharmacist (in a 2-ml syringe labeled study drug) who randomized patients and 
maintained the record for group assignment. This was the only individual with access to that 
database. Neither the investigator nor the child/parents knew the group assignment.
Exclusion criteria were presence of malignant lesions, acute infections such as sepsis or 
pneumonia, hepatic or renal failure, autoimmune diseases, and use of oral steroids within 
three months prior to surgery. The only change in eligibility criteria during the course of 
study was the enrollment of Spanish speaking patients after the approval of the consent form 
in Spanish.
Anesthetic Background
The anesthetic was standardized to consist of premedication using midazolam followed by 
induction of general anesthesia using sevoflurane in 100% inhaled oxygen prior to securing 
an intravenous line. Anesthesia was maintained using infusions of propofol at 50–100 mcg · 
kg−1 · min−1, fentanyl at 3 mcg · kg−1 · hr−1, and sevoflurane 1–2% in 50% oxygen and air. 
The baseline measurements were done following tracheal intubation and arterial line 
placement, after which either the placebo or the study drug was given intravenously.
OLV Procedure
Using a flexible pediatric bronchoscope, an Arndt endobronchial blocker (Cook Critical 
Care, Bloomington, IN, USA) was placed under direct vision to either the right or left 
mainstem bronchus via the three-way adaptor that allows uninterrupted ventilation. After the 
patients were positioned in a lateral position, the balloon was inflated under direct vision to 
block the operative-side lung. Tidal volume (TV), positive end expiratory pressure (PEEP), 
and inspired oxygen (FiO2) settings used for the study were as follows:
• Bilateral ventilation (BLV): TV, 8–10 ml/kg + PEEP, 5; FiO2, 50%
*Dixit D, Theroux MC, Shah S, Costarino A. Cardiovascular collapse in a patient undergoing single lung ventilation. ASA case 
presentation. SPA/ASA joint meeting, Oct 12, 2007, San Francisco, CA.
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• OLV: TV, 5 ml/kg + PEEP, 5; FiO2, 100%
The respiratory rate was adjusted to keep end-tidal CO2 (EtCO2) levels between 35–45 torr 
during (BLV) but was permitted to be in the range of 45–55 torr during OLV.
Outcome Measures Examined
Incidence of obstructive airway pattern was defined as: 1) a rise in EtCO2 up to 65 
mmHg or greater with an up-sloping of the EtCO2 wave form, with or without an associated 
decrease in oxygen saturation; 2) a 50% or greater rise in peak airway pressure compared to 
baseline (with no obvious occlusion of the endotracheal tube). Auscultation of lungs was not 
used as a criterion because of difficulty in accessing the chest during the procedure. Inability 
to tolerate OLV for any reason was also recorded. Respiratory mechanical parameters 
(dynamic compliance and resistance) were measured at baseline (before OLV) and 20 min 
after expansion of collapsed lung (end-OLV) using a commercially available, stand-alone 
pediatric monitoring system (CO2SMO Plus; Novametrix, Wallingford, CT, USA). The 
reported measurements were based on the average of at least 10 consecutive breaths. Peak 
inflation pressure, mean airway pressure (MAP), and blood gas parameters and glucose were 
measured at the same time points.
Measurement of Pro-Inflammatory Cytokines and Tryptase in the Plasma
The plasma cytokines were collected in blue-top tubes at time points referenced to the time 
when the study drug was administered as follows:
○ Baseline Prior to study drug administration
○ OLV20 20 min after collapse of lung
○ OLV 6hrs 6 hours after study drug administration
○ OLV 18hrs 18 hours after study drug administration
After centrifugation, the levels of TNF-α, IL-6, and IL-10 in plasma samples collected were 
measured in duplicate with quantitative ELISA using human-specific Quantikine ELISA kits 
(R&D Systems, Minneapolis, MN, USA). The test sensitivities for respective immunoassays 
were as follows: TNF-α, 1.6 pg/mL; IL-6, 0.70 pg/mL; and IL-10, 3.9 pg/mL. Inter- and 
intra-assay coefficients of variance were < 10%. Blood was drawn for tryptase levels before 
OLV and 20 minutes after onset of OLV and sent to the clinical lab (Quest Diagnostics, 
Exton, PA) for tryptase assay.
Power and Sample Size Calculation
Sample size was calculated based on the most known and frequently studied pro-
inflammatory cytokine, IL-6,9 and results of our pre-clinical study.5 To observe a difference 
in levels of IL-6 between the groups by 80%, assuming a standard deviation of 60%, risk of 
type-1 error of 5%, to achieve a power of 80%, nine patients per group was estimated.
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Statistical Analysis
Interval data (age, weight, duration of OLV, resistance, and weight-based compliance) were 
analyzed using Student t test; chi-squared test was used to analyze male-to-female ratio and 
laterality of the lung collapsed. Tryptase measured at baseline and repeated at 20 min after 
collapse of lung was analyzed using paired sample t test. Cytokine measurements were 
analyzed after Log10 transformation (to reduce the volatility and linearize the data)9 using 
repeated measures ANOVA to identify group differences as well as group · time 
interactions. The duration of OLV was used as covariate to determine its influence on the 
cytokine levels. Where significant difference occurred, the effect size was reported using 
Cohen's d or partial eta-squared as appropriate.10 All statistical analysis was done using 
SPSS 22 (IBM, Armonk, NY, USA). Probability values < 0.05 were considered significant.
Data and Safety Monitoring Plan
A Data and Safety Monitoring Board was established with the help of our IRB, and 
quarterly reports were submitted and approved by the board during the two-year study 
period.
Results
At the end of the two-year study period, 28 children had been enrolled in the study (placebo 
= 15; MP = 13). One child in each group had bilateral thoracoscopic procedures for 
recurrent blebs and was excluded from the results. The mean age and weight, ratio of male 
to female, and laterality of the lung (right/left) were not significantly different between the 
two groups (Table 1). Groups were similar for their core temperature, heart rate, mean 
arterial blood pressure, ventilatory rate, and tidal volume used (Table 2). There was no 
difference in the partial pressure of carbon dioxide or the ratio of partial pressure of oxygen 
(PaO2) to fractional concentration of oxygen (FiO2) (PF ratio) measured at any time points 
(Table 2). Glucose levels were also similar in both groups (Table 2). Surgical procedures are 
listed in Table 1.
Physiological Stability of the Subjects
No children in the MP group experienced bronchospasm, and all completed their course of 
OLV without complications. Two children in the placebo group had obstructive airway 
events during OLV with up-sloping of the EtCO2 waveform; these events were presumed to 
be due to bronchospasm. One of these two children had associated inadequate oxygenation, 
which did not improve with ketamine and epinephrine for bronchodilatation or with lung 
recruitment maneuvers, and surgery was completed via open thoracotomy. The other child 
in the placebo group who experienced bronchospasm received albuterol via endotracheal 
tube and ketamine intravenously for bronchodilatation and was able to complete the 
procedure but sustained respiratory failure and systemic inflammatory response syndrome 
(SIRS) postoperatively. A third child in the placebo group required bi-level positive airway 
pressure (BiPAP) ventilation postoperatively and also experienced SIRS. A fourth child in 
the placebo group had sub-segmental atelectasis in the right middle lobe of the collapsed 
lung and developed fever >101°F. Following cultures, he was placed on antibiotics 
empirically. He recovered without sequelae. One child in each group had minimal basilar 
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atelectasis on postoperative chest radiograph that resolved without specific treatment other 
than routine incentive spirometry.
Resistance increased from baseline to end-OLV11 as expected; however, the increase was 
ameliorated in the MP (P = 0.04 t test) compared to placebo group (Fig 1A). Weight-
adjusted compliance was decreased in both groups at end-OLV but was not significantly 
different between the groups (Fig 1B).
Mean duration of OLV was longer in the MP group, but this difference did not have a 
significant influence on any of the cytokine levels. Mean plasma level of IL-6 was greater (P 
= 0.01) in the placebo group (Fig 2A) with significant differences occurring at 6 hrs (P = 
0.03) and 18 hours (P = 0.02) after study drug administration. Mean plasma value of TNF-α 
in the MP group showed an amelioration to treatment with MP but did not achieve a 
statistically significant difference (P = 0.2) for group · time (Fig 2B). The mean plasma level 
of the anti-inflammatory cytokine IL-10 was significantly higher (P = 0.001) in the MP 
group with a significant difference (P = 0.001) occurring at 6 hours following study drug 
administration (Fig 2C).
Similarly, mean serum tryptase was significantly lower (P = 0.03) after 20 minutes of OLV 
when compared to baseline values in the MP group, showing an attenuation by MP. In 
contrast, the placebo group had a higher mean value of tryptase after 20 minutes of OLV 
when compared to the baseline values even though the difference did not achieve statistical 
significance (Fig 3). Note that the mean tryptase level in the MP group is higher than the 
mean tryptase level in the placebo group for both baseline and OLV20 values. No significant 
differences were seen when the mean values were analyzed by t test (Baseline: 1.7 ± 0.9 vs 
2.7 ± 1.5 [P = 0 .10]; OLV20: 1.8 ± 1.3 vs 2.2 ± 1.3 [P = 0.48]), indicative of a random 
occurrence.
Discussion
In this study, we have systematically examined the benefits of a single dose of MP, a well-
known anti-inflammatory agent, given prior to OLV to minimize resultant inflammatory 
injury and improve respiratory stability. We employed protective ventilation for all patients 
(as defined by the use of low-stretch ventilation of TV 5 ml/kg and PEEP of 5 cms during 
the OLV) for its known beneficial effects.9,12,13 Physiological stability of the patients during 
OLV is threatened by bronchospasm due to multiple factors such as edema, secretions, and 
reflux bronchoconstriction. OLV simulates an endobronchial intubation, which is the most 
common cause of bronchospasm in the intraoperative arena, and the beneficial effect of MP 
was evident in the lower resistance seen in the MP group after OLV, which contributed to 
the absence of bronchospasm in this group. The anti-inflammatory effects of MP in our 
study are further supported by the lower levels of IL-6 and higher levels of IL-10 in the MP 
group. Levels of IL-6 have been correlated to mortality in adults in intensive care units14 
and in children when admitted with sepsis.15
Tryptase, a protease, is familiar to anesthesiologists as a marker of an immunoglobulin E 
(IgE)-mediated reaction and bronchospasm. Tryptase elevation also occurs due to injury 
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resulting from a flux of reactive oxygen species (ROS) and resultant mast cell 
degranulation.16 Such a flux of ROS and mast cell degranulation may be anticipated during 
collapse and re-expansion of a lung, similar to that described during ischemia-reperfusion 
injuries17,18 and in hyperoxic environments.17,19 Episodes of hypoxemia that are not 
explained by the patient's preoperative conditions may occur during OLV,20 as was 
observed in two patients in the placebo group. One mechanistic pathway for such episodes 
may be the flux of ROS and related cellular events, as we observed (see footnote), where a 
healthy child experienced cardiovascular collapse shortly after re-expansion of the collapsed 
lung. Suspecting an IgE-mediated allergic reaction, we had drawn a tryptase level, which 
was elevated, and further investigation showed it to be because of a non-IgE-mediated mast 
cell degranulation. This case, along with the literature describing reperfusion injury where 
mast cells are capable of recruiting leukocytes independent of IgE mediation,16-19 helped us 
to understand the complex nature of lung injury during and after OLV. The significant 
decrease in tryptase level in the MP group after 20 minutes of OLV is a finding not 
described before in the anesthesia literature even though MP is commonly administered 
during anaphylactic episodes where mast cell degranulation is a major contributing event. 
Our choice of MP as an intervention was based on its well known ability to attenuate both 
neutrophil activation and recruitment21 and its ability to treat IgE- and non-IgE-mediated 
conditions where both basophils and mast cells degranulate.22 Methylprednisolone also has 
been shown at endothelial cell level to reduce inflammatory response23 by suppressing 
cytokine (TNF-α) production when given preoperatively in asthmatic patients. 
Methylprednisolone may down-regulate cytokine release and reduce neutrophil 
sequestration and edema.24
Procedures that necessitate OLV in children are typically different than in adults.13 Our 
understanding of OLV mostly relates to adult studies, where pneumonectomy or 
esophagectomies9,25 are often the surgical procedure. Underlying parenchymal diseases 
such as emphysema or chronic obstructive pulmonary disease are much less prevalent in 
children. Thus, pathophysiological mechanism of OLV and its treatment in adults are not 
entirely applicable to children. One lung ventilation procedures are often performed in 
children with healthy lungs, and the physiological stability that MP imparts in these patients 
may be of significant clinical value to pediatric anesthesiologists.
The drawbacks of our study are the lack of homogeneity of surgical procedures our subjects 
experienced and the small sample size. We hope to have achieved comparable groups by 
randomization of subjects, thus eliminating the selection bias and balancing the two groups 
with respect to known and unknown confounding variables. In addition, the small sample 
size increases the likelihood of type II error, leading to the inability to detect a significant 
difference when the effect size was not large. We believe that our preclinical studies in the 
animal model helped mitigate the drawbacks in our clinical study and further strengthen our 
finding.5,12,19
Conclusion
Methylprednisolone, given at 2 mg/kg before OLV, decreases the pro-inflammatory marker 
IL-6 and increases the anti-inflammatory marker IL-10 in the plasma. Further, MP decreases 
Theroux et al. Page 7
Paediatr Anaesth. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
tryptase, a marker of mast cell degranulation known to occur due to ROS during OLV. 
Overall, our study results show that a single dose of MP (2 mg/kg) given prior to OLV will 
result in greater physiological stability by minimizing bronchospasm or obstructive 
respiratory events and enabling completion of OLV.
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What is Already Known about the Subject
• One lung ventilation in children results in inflammatory injury as evidenced by 
increase in pro-inflammatory markers, which may result in intraoperative 
complications.
• In earlier studies using a piglet model of OLV, the authors have demonstrated 
that a single intravenous dose of methylprednisolone (2 mg/kg) given 
prophylactically could minimize such inflammatory injury and improve 
physiological stability of the one lung ventilation procedure.
What this Article Adds
• This manuscript describes the translational study following the animal studies 
and examines the efficacy of methylprednisolone (2 mg/kg) given 
prophylactically in minimizing inflammatory parameters, and thus improving 
physiological stability, in children undergoing one lung ventilation.
• The results show that methylprednisolone decreases pro-inflammatory markers 
including tryptase and improves physiological stability of the patients 
undergoing one lung ventilation.
Implications for Translation
• One lung ventilation results in the iatrogenic injury of various severities. As the 
injury can be anticipated, it gives the anesthesiologist a unique opportunity to 
institute measures to minimize such injury.
• Methylprednisolone (2 mg/kg) given prior to one lung ventilation decreases 
inflammatory injury and should be considered as a preventative measure prior to 
one lung ventilation in children. Other anti-inflammatory agents may have 
similar results but need further studies demonstrating their efficacy.
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Fig 1. 
Resistance (1A) and compliance (1B) measured at baseline and at termination of one lung 
ventilation (end-OLV is measured 20 minutes after re-expansion of collapsed lung). Mean ± 
SD are given. The arrow points to the placebo group measurements at end of OLV where 
the significant difference occurred (P = 0.04) as indicated by star. Note that mean resistance 
was slightly lower for the methylprednisolone group at baseline (11.2 ± 1.3 for 
methylprednisolone vs. 12.9 ± 1.5 for placebo), but it was not significantly different (P = 
0.44).
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Fig 2. 
2A: Interleukin (IL)-6 in plasma measured at baseline, 20 min after start of OLV (OLV20), 
and 6–8 hrs and 16–18 hours following administration of study drug. Mean ± SD are given. 
There was a group by time difference by repeated measures ANOVA (P = 0.01). Significant 
differences occurred between the groups at the 6-hr (P = 0.03) and 18-hrs (P = 0.02) time 
points as indicated by star (t test). Duration of OLV, which was longer in MP group, used as 
a co-variate, did not have a significant influence on the (IL)-6 values (P = 0.65). 2B: Tumor 
necrosis factor (TNF)-α in plasma measured at baseline, OLV20, and 6–8 hrs and 16–18 
hours following administration of study drug. The two groups were not significantly 
different by repeated measures ANOVA (P = 0.2). Duration of OLV, used as a co-variate, 
did not have a significant influence on the (TNF)-α values (P = 0.82). 2C: Interleukin 
(IL)-10 in plasma measured at baseline, OLV20, and 6–8 hrs and 16–18 hours following 
administration of study drug. There was a significant group by time difference analyzed by 
repeated measures ANOVA (P = 0.001). Significant difference by t test occurred between 
the groups at the 6-hr time point (P = 0.001) as indicated by star. Similar to IL-6 and (TNF)-
α analysis, duration of OLV, used as a co-variate, did not have a significant influence on the 
(IL)-10 values (P = 0.16).
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Fig 3. 
Tryptase in plasma measured at baseline and 20 min past start of OLV (OLV20). Mean ± 
SD are given. Tryptase levels were drawn at similar time points (OLV20) for all subjects 
and therefore duration of OLV is not a confounding factor for analysis of tryptase levels. 
Compared to baseline, mean tryptase at OLV20 was significantly lower (P = 0.03) by 
paired-sample t test in the MP group as indicated by star. Mean tryptase level in the MP 
group was higher than the mean tryptase level in the placebo group for both baseline and 
OLV20, which, when analyzed by t test, did not show a significant difference (1.7 ± 0.9 vs 
2.7 ± 1.5 [P = 0 .10]; OLV20: 1.8 ± 1.3 vs 2.2 ± 1.3 [P = 0.48]). We believe this is a random 
occurrence.
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Table 1
Demographic data for placebo and methylprednisolone groups.
Placebo Methylprednisolone P value
Age (years) 11.8 ± 3.8 13.6 ± 3.5 0.2
Weight (kg) 45.2 ± 25 41.8 ± 14 0.6
OLV duration (min) 95 ± 65.6 118 ± 70.4 0.4
Right/left* 9/5 5/7 0.2
Male/female 8/6 7/5 0.6
Anterior spine surgery 5 6 0.89**
Biopsy mass 7 5
Pulmonary bleb 2 1
Means and standard deviations are reported. Analytical methods used are t test and chi-square.
*
Indicates which lung was collapsed.
**
Type of surgery was analyzed by chi-square for the three types, and therefore the P value of 0.89 applies to all three surgical procedures listed.
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